Communiqués Bio-Path Holdings, Inc.

Actions

BPTH

US09057N4097

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/06/2024			Varia. 5j.	Varia. 1 janv.
2,39 ^USD	+10,65%		+3,46%	-74,19%

14/06	Bio-Path Holdings présente au congrès de l'Association européenne d'hématologie les résultats de l'étude de phase 2 en cours sur le traitement de la leucémie myéloïde aiguë par le prexigebersen en association avec la décitabine et le venetoclax	CI
03/06	Mise à jour sectorielle : Les actions du secteur de la santé gagnent en fin d'après-midi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress	14/06	AQ
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	05/06	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24	04/06	NE
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	04/06	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting	03/06	AQ
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress	24/05	AQ
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	AQ
Bio-Path: Q1 Earnings Snapshot	15/05	AQ
Bio-Path Holdings Reports First Quarter 2024 Financial Results	15/05	AQ
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024	08/05	AQ
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	22/04	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	19/04	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	18/04	AQ
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	18/04	AQ
Bio-Path Holdings Expands Global Patent Portfolio	15/04	AQ
Bio-Path Holdings Provides 2024 Clinical and Operational Update	02/04	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	27/03	NE
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	13/03	PU
Bio-Path Holdings Reports Full Year 2023 Financial Results	08/03	AQ
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	04/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bio-Path Holdings, Inc.

Actions

BPTH

US09057N4097

Communiqués

Filtres